… has been demonstrated for many cancers, including non-small-cell lung cancer (NSCLC).
The … the clinical efficacy of apatinib in patients with advanced NSCLC. Patients and methods: …

… [1] Non-small cell lung cancer (NSCLC) accounts for about 80% of … The safety and efficacy
of apatinib in combination with docetaxel in these patients were evaluated in this research. …

… In summary, our research demonstrated the high efficacy and safety of Apatinib in
patients with advanced NSCLC, especially when they suffered progression after first-line …

… regarding its use in non‑small cell lung cancer (NSCLC) … efficacy and safety of the use of
apatinib plus chemotherapy vs. chemotherapy alone for the treatment of patients with advanced‑…

… in patients with squamous NSCLC. This study assessed the efficacy and safety of camrelizumab
plus apatinib (… ) as second-line treatment in patients with advanced squamous NSCLC. …

… Patients: advanced non-small cell lung cancer with pathology or PE-CT confirmation.
Intervention: apatinib alone or apatinib plus paclitaxel/docetaxel. Control: paclitaxel/docetaxel. …

… apatinib and oral vinorelbine is potentially efficacious in the third-line setting and beyond
among patients with variation-negative advanced … option in this subset of patients. In our cohort, …

… Camrelizumab plus apatinib shows … -pretreated patients with advanced non-small cell lung
cancer (NSCLC); however, clinical benefits from this combination regimen in NSCLC patients …

… role in elderly patients remains unclear. In this study, we focused on elderly NSCLC patients,
and explored the efficacy and safety of apatinib as monotherapy when patients had failed …

… infiltration of CD8 + T cells and reducing recruitment of tumor-associated macrophages.
We … this combination in pretreated patients with advanced non–small cell lung cancer (NSCLC). …